Technical Analysis for ASND - Ascendis Pharma A/S

Grade Last Price % Change Price Change
F 131.03 -0.24% -0.32
ASND closed down 1.62 percent on Tuesday, December 3, 2024, on 60 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Flat

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish -0.24%
Upper Bollinger Band Walk Strength -0.24%
Overbought Stochastic Strength -0.24%
Down 3 Days in a Row Weakness -0.24%
200 DMA Resistance Bearish -1.86%
Stochastic Sell Signal Bearish -1.86%
Upper Bollinger Band Walk Strength -1.86%
Weak + Overbought Other -1.86%
Overbought Stochastic Strength -1.86%
Upper Bollinger Band Touch Strength -1.86%

   Recent Intraday Alerts

Alert Time
50 DMA Resistance 15 minutes ago
Fell Below Previous Day's Low 15 minutes ago
Down 1% 15 minutes ago
Fell Below 10 DMA 15 minutes ago
10 DMA Support about 23 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Ascendis Pharma A/S Description

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Life Sciences Disease Diabetes Hypertension Insulin Hormones Breakthrough Therapy Pulmonary Arterial Hypertension Drug Therapies Peptide Hormones Treatment Of Diabetes Growth Hormone Growth Hormone Deficiency Recombinant Proteins Growth Hormone Therapy Prodrug Treprostinil

Is ASND a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 161.0
52 Week Low 101.43
Average Volume 451,796
200-Day Moving Average 136.33
50-Day Moving Average 131.54
20-Day Moving Average 128.36
10-Day Moving Average 130.40
Average True Range 4.91
RSI (14) 52.83
ADX 15.36
+DI 20.46
-DI 18.05
Chandelier Exit (Long, 3 ATRs) 122.96
Chandelier Exit (Short, 3 ATRs) 132.79
Upper Bollinger Bands 136.81
Lower Bollinger Band 119.92
Percent B (%b) 0.68
BandWidth 13.16
MACD Line 1.14
MACD Signal Line 0.02
MACD Histogram 1.1242
Fundamentals Value
Market Cap 7.44 Billion
Num Shares 56.6 Million
EPS -9.21
Price-to-Earnings (P/E) Ratio -14.26
Price-to-Sales 30.12
Price-to-Book 14.55
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 137.40
Resistance 3 (R3) 137.76 136.11 136.39
Resistance 2 (R2) 136.11 134.57 135.93 136.05
Resistance 1 (R1) 133.73 133.62 132.91 133.37 135.72
Pivot Point 132.08 132.08 131.67 131.90 132.08
Support 1 (S1) 129.70 130.54 128.88 129.34 126.98
Support 2 (S2) 128.05 129.59 127.87 126.65
Support 3 (S3) 125.67 128.05 126.31
Support 4 (S4) 125.31